JHJennifer L. Herington

Jennifer L. Herington

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Jennifer L. Herington has a total of 95 co-authors. Here are the top co-authors by number of shared publications:

  • Shajila Siricilla

    Vanderbilt University Medical Center

    9 shared publications
  • Jackson H. Rogers

    Department of Pediatrics Vanderbilt University Medical Center Nashville Tennessee USA

    6 shared publications
  • Jeff Reese

    Vanderbilt Biophotonics Center Vanderbilt University Nashville Tennessee USA

    6 shared publications
  • Bibhash C. Paria

    Vanderbilt University Medical Center

    5 shared publications
  • Christopher J. Hansen

    Division of Neonatology, Department of Pediatrics, Vanderbilt University Medical Center, Nashville, TN, USA; Department of Pharmacology, Vanderbilt University, Nashville, TN, USA

    4 shared publications
  • Naoko Boatwright

    Division of Neonatology, Department of Pediatrics, Vanderbilt University Medical Center , Nashville, TN, USA

    4 shared publications

Latest Publications

  • Open Access

    Biochemical basis of cervical remodeling in preterm and term labor revealed by Raman spectroscopy

    by Rekha Gautam, Christine M. O'BRien, Ezekiel J. Haugen, Jackson H. Rogers, Laura E. Butler, Jennifer N. Bateman, Anna S. Rourke‐Funderburg, Naoko Boatwright, Wilson R. Adams, Giju Thomas, et al.

    Preterm birth (PTB), affecting approximately 15 million infants annually, is the leading cause of neonatal mortality. However, the underlying mechanisms driving preterm labor (PTL) remain poorly understood. Early detection of biomolecular changes associated with both term and PTL is critical but challenging with current methods. Here, we utilize in vivo Raman spectroscopy (RS) to non‐invasively investigate cervical remodeling in mouse models of PTL induced by inflammatory (lipopolysaccharide ‘LPS’) and hormonal (RU486) pathways, compared with term labor (TL). In vivo RS results revealed etiology‐specific biochemical differences associated with cervical remodeling. LPS‐induced PTL exhibited increased carbohydrate‐associated spectral features, whereas the RU486 model exhibited a distinct protein remodeling pattern that diverged from both LPS‐induced PTL and TL. These biochemical signatures aligned with ex vivo imaging and biomechanical assessments of collagen, elastin, and vascularity. RS differentiated PTL from TL with 86% accuracy, outperforming existing techniques. Collectively, these results demonstrate that PTL is not a single biochemical process but comprises distinct remodeling trajectories that can be detected in vivo prior to labor onset. This work establishes a translational framework for Raman‐based cervical phenotyping, supporting the future development of non‐invasive tools for early PTL detection, etiological stratification, and targeted clinical intervention, to improve maternal and neonatal outcomes.

  • Drug repurposing identifies candidate uterus-selective tocolytics for preterm labor

    by Shajila Siricilla, Christopher J. Hansen, Jeremy Staub, Jordan Walker, Alexus J. Brown, Sydney E. Cole, Debasmita De, Lauren Hatcher, Carolyn Simpson, Jackson H. Rogers, et al.

    At present, there are no US Food and Drug Administration (FDA)–approved tocolytics for the management of preterm labor. To identify drugs for repurposing as tocolytics, a phenotypic high-throughput screen against a library of 1191 FDA-approved drugs was performed for inhibitors of in vitro uterine myometrial contractions. A total of 51 drugs inhibited calcium (Ca 2+ ) mobilization in primary human myometrial cells. To minimize potential off-target effects, hit drugs were counterscreened against primary human aortic vascular smooth muscle cells, identifying 10 uterine-selective drugs. Of these, two drugs, the antiemetic fosaprepitant dimeglumine and the glucocorticoid ciclesonide, displayed favorable in vitro therapeutic indices (TIs > 5), inhibited contractions in human myometrial tissue ex vivo, and did not alter tone in the fetal murine ductus arteriosus ex vivo. Next, the potential synergy among hit drugs and clinically used tocolytics was evaluated using a high-throughput combination screen based on Ca 2+ mobilization in primary human myometrial cells. Four synergistic drug combinations incorporating ciclesonide, indomethacin, ivermectin, atosiban, or nelfinavir mesylate displayed favorable TIs of >5 and improved ex vivo tocolytic potency, efficacy, or both. Last, aprepitant, ciclesonide, and four synergistic drug combinations delayed delivery until term and improved neonatal viability and skin and lung maturation in a mouse model of induced preterm labor, with several combinations outperforming their component drugs. This approach established a systematic strategy for identifying uterus-selective tocolytics, and these findings support further preclinical development of repurposed drugs and drug combinations for the treatment of preterm labor to improve pregnancy and neonatal outcomes.

  • Caffeine-associated reduction in patent ductus arteriosus is mediated in part by adenosine receptor antagonism

    by Stacey L. Crockett, Rachel L. Su, Deanna C. Sekulich, Kierra A. Goins, Adrienne Montero, Naoko Boatwright, Courtney D. Berger, Michael T. Yarboro, Bibhash C. Paria, Jennifer L. Herington, et al.

    Caffeine is a respiratory stimulant and one of the most commonly prescribed drugs in the NICU. Primarily used to reduce apnea of prematurity, additional therapeutic benefits have been noted, including decreasing the incidence of patent ductus arteriosus. Using mouse and human ductus models, we have identified a mechanism by which caffeine can promote ductus constriction by inhibiting adenosine-mediated vasodilation.

  • Open Access

    KV7 channel activation inhibits human and murine myometrium contractility and delays delivery in a mouse model of preterm birth

    by Rachel Tribe, Yosef Mansour, Hiten Mistry, Evonne Chin-Smith, Mariola Zaleska, Deanna Sekulich, Jennifer Herington, Jeff Reese, Rima Patel, Philip Aaronson, et al.

    Despite spontaneous preterm birth (PTB, delivery < 37 weeks’ gestation) being a major contributor to perinatal morbidity and mortality worldwide, there is a paucity of treatments for treating preterm labor. We hypothesized that uterine smooth muscle (myometrium) Kv7 channels could be a therapeutic target for preventing preterm labor. Building on our previous work, we confirmed that K V 7 channels, proteins encoded by KCNQ2-5 genes and associated accessory KCNE1-5, are expressed and functional in pregnant human myometrium prior to and after the onset of labor. K V 7.2-5 activators (retigabine and ML213) effectively inhibit pregnant human and mouse myometrium contractions in vitro , and in vivo significantly delayed PTB in a non-infection preterm labor mouse model. This supports our hypothesis that augmenting K V 7 activity represents a viable mechanism to suppress uterine contractility and delay of PTB. Addressing the current drive to repurpose existing drugs for treating PTB, we propose this as a new avenue of clinical exploration. One Sentence Summary : K V 7 channel activators inhibit human uterine contractions and delay delivery in preterm mice, identifying a new target for preterm labor prevention.

  • Open Access

    Restricted mating windows and thrombospondin 2 gene deletion improve the precision of parturition timing in mice

    by Jackson H Rogers, Carmel Martin-Fairey, Naoko Boatwright, Alexus J Brown, Edie Charron, Shajila Siricilla, Ronald McCarthy, Sarah K England, Bibhash C Paria, Anita Mahadevan-Jansen, et al.

    Mice are an important model organism for studying reproduction, parturition timing, and embryonic development. Previous reports indicate that limiting mouse breeding periods can reduce variability in fetal weight. To expand on these findings, this study sought to determine whether a restricted breeding window affects mating receptivity, precision of parturition timing, and pregnancy outcomes compared to standard overnight breeding of two common wild-type strains (C57BL/6J and CD-1) of laboratory mice. Since thrombospondin 2 (Thbs2) knockout (KO) mice exhibit premature cervical remodeling without a shortened gestational length, we examined whether these mutant mice experience more precise parturition timing compared to their wild-type (WT) controls. Our findings revealed that the percentage of CD-1, but not C57BL/6J, female mice that were copulatory plug positive was significantly (P < 0.0001) reduced following a 2-h restricted mating period in the morning or evening compared to overnight breeding. Conversely, using a 2-h restricted breeding period in the morning or evening significantly (P < 0.0001) reduced the pregnancy rate of C57BL/6J, but not CD-1, female mice. Additionally, the variance in the gestational length and the timing of parturition was significantly (P < 0.0001) less in C57BL/6J and CD-1 females bred during a 2-h period in the morning compared to either strain bred overnight. Interestingly, Thbs2 KO mice mated overnight had the shortest variance in parturition times. Pregnancy outcomes were not significantly impacted by breeding schedules or Thbs2 genotype. Collectively, these data reveal that restricted mating windows and deletion of the Thbs2 gene lead to more precise timing of parturition.


  • Open Access

    Regional differences in three-dimensional fiber organization, smooth muscle cell phenotype, and contractility in the pregnant mouse cervix

    by Christopher J. Hansen, Jackson H. Rogers, Alexus J. Brown, Naoko Boatwright, Shajila Siricilla, Christine M. O’bRien, Sourav Panja, Cameron M. Nichols, Kanchana Devanathan, Benjamin M. Hardy, et al.

    The orientation and function of smooth muscle in the cervix may contribute to the important biomechanical properties that change during pregnancy. Thus, this study examined the three-dimensional structure, smooth muscle phenotype, and mechanical and contractile functions of the upper and lower cervix of nongravid (not pregnant) and gravid (pregnant) mice. In gravid cervix, we uncovered region-specific changes in the structure and organization of fiber tracts. We also detected a greater proportion of contractile smooth muscle cells (SMCs), but an equal proportion of synthetic SMCs, in the upper versus lower cervix. Furthermore, we revealed that the lower cervix had infrequent spontaneous contractions, distension had a minimal effect on contractility, and the upper cervix had forceful contractions in response to labor-inducing agents (oxytocin and prostaglandin E 2 ). These findings identify regional differences in cervix contractility related to contractile SMC content and fiber organization, which could be targeted with diagnostic technologies and for therapeutic intervention.


  • Open Access

    Arrest of mouse preterm labor until term delivery by combination therapy with atosiban and mundulone, a natural product with tocolytic efficacy

    by Shajila Siricilla, Christopher J. Hansen, Jackson H. Rogers, Debasmita De, Carolyn L. Simpson, Alex G. Waterson, Gary A. Sulikowski, Stacey L. Crockett, Naoko Boatwright, Jeff Reese, et al.


  • Open Access

    Arrest of mouse preterm labor until term delivery by combination therapy with atosiban and mundulone, a natural product with tocolytic efficacy

    by Shajila Siricilla, Christopher J. Hansen, Jackson H. Rogers, Debasmita De, Carolyn L. Simpson, Alex G. Waterson, Gary A. Sulikowski, Stacey L. Crockett, Naoko Boatwright, J. Jeffrey Reese, et al.

    Currently, there is a lack of FDA-approved tocolytics for the management of preterm labor (PL). In prior drug discovery efforts, we identified mundulone and its analog mundulone acetate (MA) as inhibitors of in vitro intracellular Ca 2+ -regulated myometrial contractility. In this study, we probed the tocolytic and therapeutic potential of these small molecules using myometrial cells and tissues obtained from patients receiving cesarean deliveries, as well as a mouse model of PL resulting in preterm birth. In a phenotypic assay, mundulone displayed greater efficacy in the inhibition of intracellular-Ca 2+ from myometrial cells; however, MA showed greater potency and uterine-selectivity, based IC 50 and E max values between myometrial cells compared to aorta vascular smooth muscle cells, a major maternal off-target site of current tocolytics. Cell viability assays revealed that MA was significantly less cytotoxic. Organ bath and vessel myography studies showed that only mundulone exerted concentration-dependent inhibition of ex vivo myometrial contractions and that neither mundulone or MA affected vasoreactivity of ductus arteriosus, a major fetal off-target of current tocolytics. A high-throughput combination screen of in vitro intracellular Ca 2+ -mobilization identified that mundulone exhibits synergism with two clinical-tocolytics (atosiban and nifedipine), and MA displayed synergistic efficacy with nifedipine. Of these synergistic combinations, mundulone + atosiban demonstrated a favorable in vitro therapeutic index (TI)=10, a substantial improvement compared to TI=0.8 for mundulone alone. The ex vivo and in vivo synergism of mundulone and atosiban was substantiated, yielding greater tocolytic efficacy and potency on isolated mouse and human myometrial tissue and reduced preterm birth rates in a mouse model of PL compared to each single agent. Treatment with mundulone 5hrs after mifepristone administration (and PL induction) dose-dependently delayed the timing of delivery. Importantly, mundulone in combination with atosiban (FR 3.7:1, 6.5mg/kg + 1.75mg/kg) permitted long-term management of PL after induction with 30 μg mifepristone, allowing 71% dams to deliver viable pups at term (> day 19, 4-5 days post-mifepristone exposure) without any visible maternal and fetal consequences. Collectively, these studies provide a strong foundation for the future development of mundulone as a stand-alone single- and/or combination-tocolytic therapy for management of PL.

  • Open Access

    Identification of mundulone and mundulone acetate as natural products with tocolytic efficacy in mono- and combination-therapy with current tocolytics

    by Shajila Siricilla, Christopher J. Hansen, Jackson H. Rogers, Carolyn L. Simpson, Stacey L. Crockett, Jeff Reese, Bibhash C. Paria, Jennifer L. Herington

    Currently, there are a lack of FDA-approved tocolytics for the management of preterm labor. We previously observed that the isoflavones mundulone and mundulone acetate (MA) inhibit intracellular Ca 2+ -regulated myometrial contractility. Here, we further probed the potential of these natural products to be small molecule leads for discovery of novel tocolytics by: (1) examining uterine-selectivity by comparing concentration-response between human primary myometrial cells and a major off-target site, aortic vascular smooth muscle cells (VSMCs), (2) identifying synergistic combinations with current clinical tocolytics to increase efficacy or and reduce off-target side effects, (3) determining cytotoxic effects and (4) investigating the efficacy, potency and tissue-selectivity between myometrial contractility and constriction of fetal ductus arteriosus (DA), a major off-target of current tocolytics. Mundulone displayed significantly greater efficacy (E max = 80.5% vs. 44.5%, p=0.0005) and potency (IC 50 = 27 μM and 14 μM, p=0.007) compared to MA in the inhibition of intracellular-Ca 2+ from myometrial cells. MA showed greater uterine-selectivity, compared to mundulone, based on greater differences in the IC 50 (4.3 vs. 2.3 fold) and E max (70% vs. 0%) between myometrial cells compared to aorta VSMCs. Moreover, MA demonstrated a favorable in vitro therapeutic index of 8.8, compared to TI = 0.8 of mundulone, due to its significantly (pex vivo mouse myometrial contractions, neither mundulone or MA affected mouse fetal DA vasoreactivity. The combination of mundulone and atosiban yielded greater tocolytic efficacy and potency on term pregnant mouse and human myometrial tissue compared to single-drugs. Collectively, these data highlight the difference in uterine-selectivity of Ca 2+ -mobilization, effects on cell viability and tocolytic efficacy between mundulone and MA. These natural products could benefit from medicinal chemistry efforts to study the structural activity relationship for further development into a promising single- and/or combination-tocolytic therapy for management of preterm labor. Chemical compounds studied in this article: atosiban (Pubchem CID: 5311010); indomethacin (Pubchem CID: 3715); mundulone (Pubchem CID: 4587968); mundulone acetate (Pubchem CID: 6857790); nifedipine (Pubchem CID: 4485); oxytocin acetate (Pubchem CID: 5771); U46619 (Pubchem CID: 5311493)

  • Open Access

    Effects of Solvents, Emulsions, Cosolvents, and Complexions on Ex Vivo Mouse Myometrial Contractility

    by Christopher J. Hansen, Shajila Siricilla, Naoko Boatwright, Jackson H. Rogers, Melissa E. Kumi, Jennifer Herington

    A great need exists to develop tocolytic and uterotonic drugs that combat poor, labor-related maternal and fetal outcomes. A widely utilized method to assess novel compounds for their tocolytic and uterotonic efficacy is the isometric organ bath contractility assay. Unfortunately, water-insoluble compounds can be difficult to test using the physiological, buffer-based, organ bath assay. Common methods for overcoming solubility issues include solvent variation, cosolvency, surfactant or complexion use, and emulsification. However, these options for drug delivery or formulation can impact tissue function. Therefore, the goal of this study was to evaluate the ability of common solvents, surfactants, cosolvents, and emulsions to adequately solubilize compounds in the organ bath assay without affecting mouse myometrial contractility. We found that acetone, acetonitrile, and ethanol had the least effect, while dimethylacetamide, ethyl acetate, and isopropanol displayed the greatest inhibition of myometrial contractility based on area under the contractile curve analyses. The minimum concentration of surfactants, cosolvents, and human serum albumin required to solubilize nifedipine, a current tocolytic drug, resulted in extensive bubbling in the organ bath assay, precluding their use. Finally, we report that an oil-in-water base emulsion containing no drug has no statistical effect beyond the control (water), while the drug emulsion yielded the same potency and efficacy as the freely solubilized drug.